These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 16722544)

  • 21. Targeting epidermal growth factor receptor in head and neck cancer.
    Ford AC; Grandis JR
    Head Neck; 2003 Jan; 25(1):67-73. PubMed ID: 12478546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.
    Smilek P; Neuwirthova J; Jarkovsky J; Dusek L; Rottenberg J; Kostrica R; Srovnal J; Hajduch M; Drabek J; Klozar J
    Neoplasma; 2012; 59(5):508-15. PubMed ID: 22668015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.
    Herbst RS; Kim ES; Harari PM
    Expert Opin Biol Ther; 2001 Jul; 1(4):719-32. PubMed ID: 11727507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling.
    Hasselbalch B; Lassen U; Poulsen HS; Stockhausen MT
    Cancer Invest; 2010 Oct; 28(8):775-87. PubMed ID: 20504227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
    Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
    Albanell J; Codony-Servat J; Rojo F; Del Campo JM; Sauleda S; Anido J; Raspall G; Giralt J; Roselló J; Nicholson RI; Mendelsohn J; Baselga J
    Cancer Res; 2001 Sep; 61(17):6500-10. PubMed ID: 11522647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cetuximab in squamous cell carcinoma of the head and neck.
    Hitt R; Martín P; Hidalgo M
    Future Oncol; 2006 Aug; 2(4):449-57. PubMed ID: 16922611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
    Saba NF; Khuri FR; Shin DM
    Oncology (Williston Park); 2006 Feb; 20(2):153-61; discussion 162, 166, 169 passim. PubMed ID: 16562649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor targeted therapies for solid tumours.
    Van den Eynde M; Baurain JF; Mazzeo F; Machiels JP
    Acta Clin Belg; 2011; 66(1):10-7. PubMed ID: 21485758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines.
    Song JI; Lango MN; Hwang JD; Drenning SD; Zeng Q; Lamph WW; Grandis JR
    Cancer Res; 2001 Aug; 61(15):5919-25. PubMed ID: 11479234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Zibelman M; Mehra R
    Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti- or pro-proliferation—conditional options for TGF-α and cetuximab in head and neck squamous cell carcinoma.
    Ekblad L; Welinder C; Kjellén E; Brun E; Wennerberg J
    Oral Oncol; 2015 Jan; 51(1):46-52. PubMed ID: 25261297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of epidermal growth factor receptor biology.
    Herbst RS
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):21-6. PubMed ID: 15142631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
    Jedlinski A; Ansell A; Johansson AC; Roberg K
    J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of epidermal growth factor receptor in head and neck squamous cell carcinoma.
    Pomerantz RG; Grandis JR
    Curr Oncol Rep; 2003 Mar; 5(2):140-6. PubMed ID: 12583831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
    Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
    Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma.
    Oliveira-Silva RJ; Carolina de Carvalho A; de Souza Viana L; Carvalho AL; Reis RM
    Recent Pat Anticancer Drug Discov; 2016; 11(2):170-83. PubMed ID: 26955963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.